Ionis Pharmaceuticals (IONS) Asset Writedowns and Impairment (2015 - 2026)

Ionis Pharmaceuticals' Asset Writedowns and Impairment history runs 12 years deep, the most recent figure standing at $40000.0 for Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment fell 34.43% year-over-year to $40000.0 in Q1 2026; TTM through Mar 2026 was $965000.0, a 67.4% decrease from a year earlier, with the FY2025 full-year figure at $986000.0, down 67.48% from the prior year.
• Asset Writedowns and Impairment retreated to $40000.0 in Q1 2026 per IONS's latest filing, from $4.6 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $4.6 million in Q4 2025 and bottomed at -$3.9 million in Q3 2025.
• The 5-year median for Asset Writedowns and Impairment is $256000.0 (2024), against an average of $465294.1.
• Across the five-year window, Asset Writedowns and Impairment soared 737.84% in 2024 and slumped 735.48% in 2025, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at $875000.0 in 2022, then grew by 11.2% to $973000.0 in 2023, then jumped by 107.91% to $2.0 million in 2024, then soared by 128.82% to $4.6 million in 2025, then sank by 99.14% to $40000.0 in 2026.
• Per Business Quant, the three latest IONS Asset Writedowns and Impairment figures stand at $40000.0 (Q1 2026), $4.6 million (Q4 2025), and -$3.9 million (Q3 2025).